ECOG randomized patients with advanced NSCLC to 1 of 4 new 3 of the 4 regimens used in ECOG docetaxel/cisplatin, paclitaxel/cisplatin. In the ECOG trial, the only direct comparison of similar regimens, response rates and survival times were similar between patients treated with cisplatin. ECOG was chosen as a plenary session presentation because it is an important trial that reflects the state of care in of metastatic NSCLC—the.

Author: Zolojin Kigazilkree
Country: Maldives
Language: English (Spanish)
Genre: Career
Published (Last): 17 June 2018
Pages: 69
PDF File Size: 8.97 Mb
ePub File Size: 8.13 Mb
ISBN: 168-7-60616-175-8
Downloads: 47323
Price: Free* [*Free Regsitration Required]
Uploader: Zuzilkree

While some of this is likely due to better drugs, much of the gain is from stage migration.

Lung Cancer Highlights

Lung cancer mortality in European regions — Grade 3 or 4 neutropenia, anemia, nausea and vomiting, and constipation were more common with VC, while grade 3 or 4 thrombocytopenia was more common with PCb and GC.

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. ECOG registered patients into the initial therapy with etoposide and cisplatin. Jpn J Cancer Res. The remainder of toxicity was well balanced between all three groups, with the exception of more diarrhea in the antibody arms. Performance status as a prognostic factor. In recent years, the rapidly expanding knowledge of cancer pathogenesis at a molecular level has provided new targets for drug discovery, and a great number of new anti-cancer drugs have been developed.

J Clin Pharm Pract ; 3: The outcome of 64 PS2 patients enrolled in the clinical trial ECOG comparing four platinum-based combinations has been analysed in detail, after the accrual of PS2 patients had been stopped because of the perception of an excessive number of adverse events in this sub-group [ 27 ].


In conclusion, docetaxel has markedly impacted the treatment of advanced NSCLC and continued evaluation in earlier-stage disease is warranted. ECOG was chosen as a plenary session presentation because it is an important trial that reflects the state of care in of metastatic NSCLC—the leading cause of cancer-related death in North America. The primary endpoint of this trial was survival, with response rate, time to progression and toxicity assessment being secondary endpoints.

Pharmacokinetics and pharmacodynamics of the taxanes. Docetaxel is also commonly used as part of a combined modality regimen in locally or regionally advanced disease, with notable results as consolidation therapy. These data should of course be kept in mind when treating PS2 patients, who are at a higher risk of toxicity.

While response rate is a useful surrogate marker, survival is ultimately the best indicator of the success or failure of a treatment. Consensus on clinical research.

Grade 3 or 4 alopecia was more common with PCb. Disappointingly, data about QoL are scanty.

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. Evidence available for each of the following six topics in the treatment of PS2 patients was reviewed: In fact, patients treated with docetaxel consistently reported improvements in global QOL, while vinorelbine-treated patients consistently reported deteriorating QOL [ 13 ].

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: Selected toxicities from ECOG User Name Password Sign In. Some of the data considered by the panellists still lack peer-review quality and are possibly not definitive. Two hundred twenty-seven patients were randomized to either observation or topotecan.

  ASTM C1012 PDF

Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review

All the panellists participating in the meeting agreed that an important prognostic and predictive help for clinical management could derive from a proper sub-classification of PS2 patients. Clearly we have reached our limit in developing doublet platinum-based combinations for advanced NSCLC. In her commentary on this study, Dr.

A Southwest Oncology Group Trial. Overall survival was the primary efficacy end point. Previous Section Next Section.

Lung Cancer Highlights

Taxotere docetaxel injection concentrate. Crossover and QOL data were not reported in this study [ 15 ]. In all the retrospective and prospective trials regarding prognostic factors in this disease, PS has been shown to be an independent prognostic parameter [ 19 — 25 ].

Identify key efficacy findings from the four large randomized trials assessing platinum-taxane combinations in advanced NSCLC. However, the impressive response rate and the unusual cavitation seen in these lesions is supportive of this drug having activity. Nearly all trials showed some benefit in terms of QoL and symptomatic improvement favouring chemotherapy against supportive care alone, but only one study [ 29 ] specifically analysed QoL in the different PS sub-groups.

Enrollment required a PS score of 0 or 1. The study enrolled patients with a PS of between 0 and 2. This exog is due in a large part to patient selection.

Activity of docetaxel in platinum-treated non-small-cell lung cancer: